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Metformin Treatment in Patients with Type 2 Diabetes 
and Chronic Kidney Disease Stages 3A, 3B, or 4
The safety of metformin was examined in moderate and 
severe chronic kidney disease (CKD)( stages 3A/3B and 4, 
eGFR 59-45, 44-30, and <15 mL/min/1.72 m2, respectively). 
Three metformin doses were examined: 1,500mg (0.5g in the 
morning [qam]+ 1g in the evening [qpm]) in CKD3A, 1,000 
mg (0.5g qam + 0.5g qpm ) in CKD3B, and 500 mg (qam) in 
CKD 4. After 4 months on these regimens, patients displayed 
stable metformin concentrations that never exceeded the 
safe upper limit of 5.0 mg/L. Hyperlactatemia was absent, 
and HbA1c levels did not change. The study provided solid 
basis for the continuing metformin treatment in patients with 
moderate or severe CKD, supporting the recent guidelines on 
metformin treatment, providing that the dose is adjusted to 
the eGFR (Lalau JD et al, Diabetes Care 2018;43:547-553).
How Does Empagliflozin Reduce Cardiovascular 
Mortality? Insights From a Mediation Analysis  
of the EMPA-REG OUTCOME Trial
Empagliflozin was the first glucose-lowering agent to dem-
onstrate a reduction in cardiovascular (CV) death in patients 
with type 2 diabetes and high CV risk. In the EMPA-REG 
OUTCOME trial, over a median observation time of 3.1 years, 
treatment with empagliflozin vs placebo in addition to standard 
care led to 14% reduction in the risk of CV death, nonfatal 
myocardial infarction, and nonfatal death. A small increase 
of hematocrit (and hemoglobin) appeared to be the variable 
with the largest impact on the reduction of CV death. Variables 
related to glycemia had smaller mediating effects. Changes 
on some traditional CV risk factors, including obesity, blood 
pressure, lipids, and renal function, made negligible contri-
butions (Inzucchi S et al, Diabetes Care 2018;41:356-363).
Efficacy and Safety if Once-Weekly Semaglutide 
Versus Exenatide ER in Subjects With Type 2 Diabetes 
(SUSTAIN 3): A 56-Week, Open-Label, Randomised 
Clinical Trial
In this phase 3a, open-label, parallel-group, randomized 
controlled trial, 813 subjects with type 2 diabetes taking oral 
antidiabetic drugs were randomized (1:1) to semaglutide 1.0 
mg or exenatide ER 2.0 mg for 56 weeks. Mean HbA1c was 
reduced by 1.5% with semaglutide vs 0.9% with exenatide 
ER (P<0.0001). Mean body weight was reduced by 5.6 kg 
with semaglutide vs 1.9 kg with exenatide ER (P<0.0001). 
Significantly more patients taking semaglutide achieved the 
goal of Hba1c <7.0%. Both treatments had similar safety pro-
files, yet gastrointestinal adverse effects were more common 
in semaglutide-treated participants (Ahmann A et al, Diabetes 
Care 2018;41:258-266).
Standards of Medical Care in Diabetes - 2018
The new 2018 recommendations include advances in car-
diovascular disease risk management. Based upon the results 
of multiple cardiovascular outcome trials, it is recommended 
that in people with heart disease, after lifestyle management 
and metformin, a medication validated to improve heart health, 
such as liraglutide and/or empagliflozin should be included. 
Most adults with diabetes and hypertension should have a 
target blood pressure of <140/90 mmHg. Lower targets, such 
as 130/80, may be appropriate for some high-risk patients. 
Testing for prediabetes and type 2 diabetes should be consid-
ered in children and adolescents younger than 18 years who 
are overweight or obese and have one or more additional risk 
factors for diabetes. Health care providers need to be aware of 
the limitations regarding HbA1c test use and consider alternate 
diagnostic tests (fasting plasma glucose or oral glucose toler-
ance test) if there is a disagreement between A1c and blood 
glucose levels (Diabetes Care 2018;41 Suppl 1).
Efficacy and safety of sodium-glucose contrasporter-2 
inhibitors versus dipeptidyl peptidase-4 inhibitors as 
monotherapy or add-on to metformin in patients with 
type 2 diabetes mellitus: A systemic review and meta-
analysis
In this meta-analysis of randomized controlled trials, the ef-
ficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP-4is) 
and sodium-glucose contrasporter-2 inhibitors (SGLT-2is) as 
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monotherapy or add-on to metformin were assessed in patients 
with type 2 diabetes. Combination therapy with metformin and 
DPP-4is led to a statistically significant decrease of HbA1c by 
-0.55% compared to metformin monotherapy. Similar results 
were seen with the SGLT-2is combination with metformin; 
combination therapy reduced HbA1c levels by 0.55%. Dual 
therapy with metformin and SGLT-2 also offers increased 
body weight loss by 1.82 kg (p<0.0000.) as compared to 
metformin alone. More important, SGLT-2is were associated 
with a significantly stronger reduction in HbA1c and fasting 
plasma glucose than were DPP-4is. There was no difference 
in the risk for hypoglycemic events (Wang Z et al, Diabetes 
Obes Metab 2018;20:113-120).
Cardiovascular and renal burdens of prediabetes in 
the USA: analysis of data from serial cross-sectional 
surveys, 1988-2014
Using data from US National Health and Nutrition Ex-
amination Surveys (NHANES) between 1988 and 2014, the 
researchers examined the cardiovascular and renal burdens 
in adults with prediabetes over time and compared patterns 
with other glycemic status groups. This study analyzed data 
for 27,971 adults (over 19 years of age), excluding pregnancy. 
Individuals diagnosed with diabetes were more likely to 
receive blood pressure-lowering and cholesterol-lowering 
therapy compared with individuals with prediabetes. Adults 
diagnosed with prediabetes showed significantly higher renal 
and cardiovascular disease risk (Ali MK et al, Lancet Diabetes 
Endocrinol. 2018 May;6:392-403)
Risk of Cardiovascular Disease and Death in Individuals 
with Prediabetes Defined by Different Criteria:  
The Whitehall II Study
In this Whitehall II cohort study, 5,427 participants be-
tween the ages of 50-79 years with prediabetes were enrolled 
and followed for mean of 11.5 years. The study compared the 
risk of fatal or nonfatal CVD or all-cause mortality in indi-
viduals with prediabetes identified by FPG, 2hPG or HbA1c. 
Prediabetes can be defined using HbA1c, fasting plasma 
glucose (FPG) or 2-hr plasma glucose (2hPG). According 
to World Health Organization (WHO) / International Expert 
Committee (IEC), prediabetes is defined as FPG 6.1–6.9 
mmol/L and/or HbA1c 6.0–6.4%. According to the American 
Diabetes Association (ADA), prediabetes is defined as FPG 
5.6–6.9 mmol/L and/or HbA1c 5.7–6.4%. Prediabetes defined 
by using the ADA criteria displayed lower risk of developing 
CVD or mortality than when prediabetes is defined using 
WHO/IEC criteria. HbA1c was more accurate in predicting 
CVD and mortality risk in individuals with prediabetes than 
FPG or 2hPG concentration (Vistisen D et al, Diabetes Care 
2018;41:899-909).
Dipeptidyl peptidase-4 inhibitors and incidence of 
inflammatory bowel disease among patients with  
type 2 diabetes: population based cohort study
This cohort study assessed whether the use of dipeptidyl 
peptidase-4 inhibitors is related to the incidence of inflamma-
tory bowel disease in patients with type 2 diabetes. Prolonged 
use of DPP-4 inhibitors in patients with type 2 diabetes is 
associated with an overall 75% increase in the risk of inflam-
matory bowel disease, more than a twofold increase in the risk 
of ulcerative colitis and no difference in the risk for Crohn’s 
disease. Although the absolute risk is low, physicians should 
be aware of this possible association and perhaps refrain from 
prescribing dipeptidyl peptidase-4 inhibitors for people at high 
risk (that is, those with a family history of disease or with 
known autoimmune conditions). Moreover, patients presenting 
with persistent gastrointestinal symptoms, such as abdominal 
pain or diarrhea, should be closely monitored for worsening of 
symptoms (Abrahami DA et al, BMJ 2018;360;k872).
